Wednesday, October 28, 2026
Data from SEC filings, checked daily
Public filings, plainly told
AboutMethodSourcesNewsletter
StockCIK 1601830

RECURSION PHARMACEUTICALS, INC. (RXRX): Insider Trades and Fund Holdings

In the past 12 months, RECURSION PHARMACEUTICALS, INC. insiders reported 0 open-market purchases worth $0 and 4 sales worth $546K; 4 of the sales were reported as made under a 10b5-1 trading plan.

0Insider buys, 12 months
$0Bought by insiders, 12 months
$546KSold by insiders, 12 months
1Tracked funds holding

Timeline: news and trades

Company filings (8-K), insider trades, notices of planned sales (Form 144) and fund moves in the past year, newest first.

  1. Oct 15, 2026NewsCompany reported: Signed a material agreement; Quarterly or annual results
  2. Oct 6, 2026Insider saleDirector Blake Borgeson sold $242,000 under a 10b5-1 plan
  3. Oct 6, 2026Insider saleDirector Robert Hershberg sold $125,000 under a 10b5-1 plan
  4. Oct 6, 2026Planned saleBorgeson Blake (director) filed notice to sell about $242,000 around Oct 6, 2026
  5. Oct 6, 2026Planned saleHERSHBERG ROBERT (director) filed notice to sell about $125,000 around Oct 6, 2026
  6. Sep 21, 2026NewsCompany reported: Signed a material agreement
  7. Sep 8, 2026Insider saleCEO Najat Khan sold $78,822 under a 10b5-1 plan
  8. Sep 1, 2026Insider saleDirector Blake Borgeson sold $100,200 under a 10b5-1 plan
  9. Jun 30, 2026FundBridgewater Associates opened a position in Q2 2026 (13F filed Aug 14, 2026)
  10. Jun 30, 2026FundRenaissance Technologies sold out in Q2 2026 (13F filed Aug 13, 2026)

Recent insider trades

Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 7, 2026.

Recent RXRX insider trades
FiledTradedInsiderRoleTypeSharesPrice ($)ValueHoldingFiling
Oct 7Oct 6Blake BorgesonDirectorDirector▼ SELL10b5-150,0004.84$242K−0.8%Form 4 ↗
Oct 7Oct 6Robert HershbergDirectorDirector▼ SELL10b5-125,0005.00$125K−13%Form 4 ↗
Sep 10Sep 8Najat KhanCEOCEO▼ SELL10b5-122,4083.52$79K−1.1%Form 4 ↗
Sep 2Sep 1Blake BorgesonDirectorDirector▼ SELL10b5-130,0003.34$100K−0.5%Form 4 ↗
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings

Insiders who traded in the past year

InsiderRoleBuysBoughtSellsSoldLatest
Blake BorgesonDirector0$02$342KOct 7, 2026
Robert HershbergDirector0$01$125KOct 7, 2026
Najat KhanCEO0$01$79KSep 10, 2026

Buybacks and executive pay

YearCEO pay reportedCEO pay "actually paid"Value of $100 invested
2025$9.61M$3.48Mn/a
2024$8.50M$1.91Mn/a
2023$8.61M$10.7Mn/a

From the company's XBRL data filed with the SEC. "Actually paid" is the SEC's pay-versus-performance measure, which counts changes in the value of stock awards. "Value of $100 invested" is the company's cumulative shareholder return as reported, usually measured from five years earlier. See all buybacks and CEO pay across companies.

Tracked funds that report RXRX

From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.

FundQuarterSharesValue% of portfolioChange
Bridgewater AssociatesQ2 202637,667$138K0.00%▲ New
Renaissance TechnologiesQ2 20260$00.00%▼ Sold out
Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings

Reading these numbers

Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →